Skip to main content
    I

    Inspire Medical Systems Inc (INSP)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $59.07
    -2.03 (-3.32%)

    Market Cap: $1.77B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Inspire Medical Systems Inc (INSP) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Inspire Medical Systems (INSP) is expected to report earnings on May 3, 2027. In the quarter ended Sep 30, 2026, Inspire Medical Systems reported EPS of $0.14, above the $0.10 estimate. It beat the EPS estimate in each of the last 26 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    94%(33/35)
    Avg Surprise
    +100.12%
    Streak
    26 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.73
    Range$0.33 - $0.96
    19 analysts
    Revenue Consensus
    $247.50M
    Range$225.40M - $258.30M
    18 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.13
    Range-$0.13 - $0.34
    10 analysts
    EPS Estimate DriftChange to current
    90d ago$0.15-16.1%
    60d ago$0.15-16.1%
    30d ago$0.15-16.1%
    7d ago$0.15-16.1%
    Current$0.13
    Revenue Consensus
    $192.40M
    Range$184.84M - $200.30M
    10 analysts

    Next Report

    INSP has an expected report date of May 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 55.8% below the $1.65 reported for the quarter ended Dec 31, 2025.

    INSP Earnings Call

    The latest INSP earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 35 quarters below that had an estimate, INSP beat 33 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $206.69M, down 7.9% from $224.50M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.14$0.10-$0.13 - $0.17+40.00%Beat-63.2%142 up, 8 downNov 2, 2026$206.69M
    Jun 30, 2026$0.14-$0.22-$0.38 - -$0.19+163.64%Beat-68.9%131 up, 1 downAug 3, 2026$200.58M
    Mar 31, 2026$0.10-$0.26-$0.41 - -$0.05+138.46%Beat0.0%121 up, 1 downMay 4, 2026$204.58M
    Dec 31, 2025$1.65$0.68$0.61 - $0.73+142.65%Beat+43.5%125 up, 0 downFeb 11, 2026$269.08M
    Sep 30, 2025$0.38-$0.17-$0.22 - -$0.03+323.53%Beat-36.7%101 up, 1 downNov 3, 2025$224.50M
    Jun 30, 2025$0.45$0.20$0.12 - $0.27+125.00%Beat+40.6%140 up, 1 downAug 4, 2025$217.09M
    Mar 31, 2025$0.10-$0.23-$0.35 - -$0.15+143.48%BeatN/A140 up, 1 downMay 5, 2025$201.32M
    Dec 31, 2024$1.15$0.72$0.63 - $0.81+59.72%Beat+134.7%135 up, 1 downFeb 10, 2025$239.72M
    Sep 30, 2024$0.60$0.08$0.01 - $0.30+650.00%BeatN/A160 up, 0 downNov 4, 2024$203.19M
    Jun 30, 2024$0.32-$0.11-$0.39 - -$0.02+390.91%BeatN/A171 up, 1 downAug 6, 2024$195.88M
    Mar 31, 2024-$0.34-$0.67-$0.85 - -$0.41+49.25%BeatN/A170 up, 0 downMay 7, 2024$164.01M
    Dec 31, 2023$0.49-$0.09-$0.35 - $0.18+644.44%Beat+390.0%116 up, 1 downFeb 6, 2024$192.51M
    Sep 30, 2023-$0.29-$0.57-$0.80 - -$0.37+49.12%BeatN/A130 up, 1 downNov 7, 2023$153.30M
    Jun 30, 2023-$0.41-$0.58-$0.88 - -$0.40+29.31%BeatN/A131 up, 0 downAug 1, 2023$151.09M
    Mar 31, 2023-$0.53-$0.70-$0.91 - -$0.30+24.29%BeatN/A120 up, 0 downMay 2, 2023$127.90M
    Dec 31, 2022$0.10-$0.54-$0.87 - -$0.20+118.52%BeatN/A104 up, 0 downFeb 7, 2023$137.90M
    Sep 30, 2022-$0.60-$0.79-$0.90 - -$0.48+24.05%BeatN/A100 up, 0 downNov 1, 2022$109.19M
    Jun 30, 2022-$0.53-$0.63-$0.71 - -$0.46+15.87%BeatN/A110 up, 0 downAug 2, 2022$91.39M
    Mar 31, 2022-$0.61-$0.83-$1.04 - -$0.47+26.51%BeatN/A100 up, 0 downMay 3, 2022$69.38M
    Dec 31, 2021-$0.09-$0.46-$0.60 - -$0.21+80.43%BeatN/A104 up, 0 downFeb 8, 2022$78.40M
    Sep 30, 2021-$0.38-$0.64-$0.79 - -$0.44+40.63%BeatN/A11N/ANov 2, 2021$61.69M
    Jun 30, 2021-$0.48-$0.66-$0.76 - -$0.47+27.27%BeatN/A11N/AAug 3, 2021$52.96M
    Mar 31, 2021-$0.60-$0.64-$0.90 - -$0.51+6.25%BeatN/A11N/AMay 4, 2021$40.35M
    Dec 31, 2020-$0.28-$0.48-$0.77 - -$0.32+41.67%BeatN/A13N/AFeb 23, 2021$46.01M
    Sep 30, 2020-$0.39-$0.73-$0.82 - -$0.63+46.58%BeatN/A13N/ANov 2, 2020$35.84M
    Jun 30, 2020-$0.88-$1.14-$1.20 - -$0.79+22.81%BeatN/A10N/AAug 4, 2020$12.18M
    Mar 31, 2020-$0.67-$0.60-$0.74 - -$0.27-11.67%MissN/A9N/AMay 5, 2020$21.35M
    Dec 31, 2019-$0.38-$0.40-$0.55 - -$0.34+5.00%BeatN/A8N/AFeb 25, 2020$26.91M
    Sep 30, 2019-$0.34-$0.41-$0.48 - -$0.35+17.07%BeatN/A7N/ANov 5, 2019$20.86M
    Jun 30, 2019-$0.32-$0.43-$0.47 - -$0.37+25.58%BeatN/A7N/AAug 6, 2019$18.03M
    Mar 31, 2019-$0.35-$0.38-$0.47 - -$0.29+7.89%BeatN/A7N/AMay 7, 2019$16.25M
    Dec 31, 2018-$0.22-$0.31-$0.39 - -$0.24+29.03%BeatN/A7N/AFeb 26, 2019$16.56M
    Sep 30, 2018-$0.22-$0.34-$0.37 - -$0.33+35.29%BeatN/A5N/ANov 6, 2018$13.05M
    Jun 30, 2018-$0.43-$0.48N/A+10.42%BeatN/A4N/AAug 7, 2018$10.94M
    Mar 31, 2018-$5.05-$3.64-$5.40 - -$0.32-38.74%MissN/A3N/AMay 4, 2018$10.04M
    Dec 31, 2017-$3.46N/AN/AN/AN/AN/AN/AN/AFeb 28, 2018$9.96M
    Mar 31, 2017-$3.90N/AN/AN/AN/AN/AN/AN/AJun 29, 2017$5.30M
    Last 37 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.58, up 49.1% from the year before. It was -$7.36 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.58+49.1%
    Dec 31, 2024$1.73N/A
    Dec 31, 2023-$0.74N/A
    Dec 31, 2022-$1.64N/A
    Dec 31, 2021-$1.55N/A
    Dec 31, 2020-$2.22N/A
    Dec 31, 2019-$1.39N/A
    Dec 31, 2018-$5.92N/A
    Dec 31, 2017-$7.36N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 20 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,03920
    2026Q2Jun 30, 20267,17018
    2026Q1Mar 31, 20267,05319
    2025Q4Dec 31, 20257,54015
    2025Q3Sep 30, 20258,34220
    2025Q2Jun 30, 20258,36418
    2025Q1Mar 31, 20257,09620
    2024Q4Dec 31, 20247,36316

    2026Q3 Earnings Call

    Opening remarks

    Louisa Smith Moderator Thank you, Dilem. Joining me on today's call are Tim Herbert, Chairman and Chief Executive Officer, and Matt Osberg, Chief Financial Officer. Earlier today, we released financial results for the three months ended September 30, 2026. A copy of the press release is available on our website. On this call, management will make forward-looking statements within the meaning of federal securities laws. All forward-looking statements, including without limitation, those relating to our operations, financial results, financial condition, investments in our business, financial and operational outlook for 2026 and future periods, and changes in market access and different aspects of coding or reimbursement, are based upon our current estimates and various assumptions. Forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. For discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission, including our periodic reports on Form 10-K and 10-Q, as well as the Form 10-Q, which we filed this afternoon with the SEC for the quarter ended September 30, 2026. Inspire disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and speaks only as of the live broadcast today, November 2, 2026. With that, I will turn the call over to Tim. Go ahead.

    Tim Herbert Chairman and CEO Thanks, Louisa. Thank you to everyone for joining today's call. To start, the focus of our employees and the physician and care teams we work with is delivering the best possible outcomes for patients. OSA, a largely untreated condition, and the more we learn about it, the clearer it becomes that its impact goes beyond sleep to a patient's underlying health. Our Inspire therapy is the market leader for hypoglossal nerve stimulation treatment for OSA, and we believe that better treatment leads to better sleep, which leads to better health. This belief shapes how we approach everything we do. For the third quarter, we were pleased to deliver revenue and adjusted operating income slightly ahead of our expectations, with another strong quarter of operating cash flow and a 3% sequential revenue increase. Coding has been a central topic this year, so I'll provide an update using the same near-, mid-, and long-term lens we shared in August. In the near term, we continue to work closely with physicians and staff on the new billing procedures. As with any abrupt workflow change, it took time for implanting sites to get comfortable with the new rules.

    Frequently Asked Questions About INSP

    When is Inspire Medical Systems's next earnings date?

    Inspire Medical Systems's next earnings report is expected for May 3, 2027.

    Did INSP beat earnings estimates last quarter?

    Yes. Inspire Medical Systems reported EPS of $0.14 for the quarter ended Sep 30, 2026, above the $0.10 estimate, a 40.00% surprise.

    What EPS do analysts expect from INSP next quarter?

    The consensus EPS estimate for Inspire Medical Systems for the quarter ending Dec 31, 2026 is $0.73 from 19 analysts, with estimates from $0.33 to $0.96.

    How often does INSP beat earnings estimates?

    Inspire Medical Systems beat the EPS estimate in each of the last 26 quarters, with an average surprise of +131.71%.